Unique ID issued by UMIN | UMIN000058600 |
---|---|
Receipt number | R000067004 |
Scientific Title | A retrospective study to evaluate the tolerability of outpatient initiation of platinum-based combination therapy with carboplatin |
Date of disclosure of the study information | 2025/07/25 |
Last modified on | 2025/07/25 18:23:15 |
A retrospective study to evaluate the tolerability of outpatient initiation of platinum-based combination therapy with carboplatin
A retrospective study on the safety of carboplatin-based chemotherapy initiation in outpatient settings
A retrospective study to evaluate the tolerability of outpatient initiation of platinum-based combination therapy with carboplatin
A retrospective study on the safety of carboplatin-based chemotherapy initiation in outpatient settings
Japan |
Non-small cell lung cancer
Pneumology | Chest surgery |
Malignancy
NO
Evaluation of the tolerability of outpatient initiation of first-line carboplatin-based combination therapy in patients with advanced or recurrent non-small cell lung cancer.
Safety
Completion rate of 4 chemotherapy courses
Unscheduled medical visit rate up to 4 cycles, Adverse events of grade 3 or higher, Progression-free survival, Overall survival, Dose reduction rate during 4 cycles of treatment
Observational
Not applicable |
Not applicable |
Male and Female
Eligible cases are those who meet either (1) or (2) below and also meet (3).
(1) Patients with advanced or recurrent non-small cell lung cancer with a performance status (PS) of 0-1 who have started initial systemic chemotherapy with a regimen containing carboplatin.
(2) Patients with advanced or recurrent non-small cell lung cancer with a PS of 0-1 who have started initial systemic chemotherapy with a regimen containing carboplatin after molecular targeted drug therapy.
(3) Patients who started initial treatment between January 1, 2019 and December 31, 2022.
Patients who meet any of the following criteria will be excluded.
Those who have expressed refusal to participate in this study through a disclosure document.
Cases in which initial systemic chemotherapy was administered after unplanned emergency hospitalization.
Those treated with the Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel (ABCP) regimen (In reality, it takes more than 5-6 hours to administer the drugs, making it difficult to administer the regimen in an outpatient chemotherapy room. Therefore, it is not possible to compare the outpatient and inpatient groups.)
400
1st name | Takuji |
Middle name | |
Last name | Suzuki |
Chiba University Hospital
Department of Respiratory medicine
260-8677
1-8-1, Inohana, Chuo-ku, Chiba city, Chiba
043-222-7171
suzutaku@chiba-u.jp
1st name | Fujihiro |
Middle name | |
Last name | Kure |
Chiba University Hospital
Department of Respiratory medicine
260-8677
1-8-1, Inohana, Chuo-ku, Chiba city, Chiba
043-222-7171
23fd0146@student.gs.chiba-u.jp
Chiba University Hospital
Chiba University Hospital
Other
Funabashi Municipal Medical Center, Chiba Cancer Center Research Institute
None
The Research Ethics Committees of Graduate School of Medicine, Chiba University
1-8-1, Inohana, Chuo-ku, Chiba city, Chiba
043-222-7171
inohana-rinri@chiba-u.jp
NO
2025 | Year | 07 | Month | 25 | Day |
Unpublished
344
No longer recruiting
2024 | Year | 09 | Month | 26 | Day |
2024 | Year | 09 | Month | 26 | Day |
2024 | Year | 09 | Month | 26 | Day |
2025 | Year | 03 | Month | 30 | Day |
2025 | Year | 03 | Month | 30 | Day |
2025 | Year | 03 | Month | 30 | Day |
None
2025 | Year | 07 | Month | 25 | Day |
2025 | Year | 07 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067004